# Inspire Medical drops despite analyst buy rating

> Stock falls 5.2% even as Freedom Capital Markets initiates bullish coverage with $97 price target.
- Title: Inspire Medical drops despite analyst buy rating | Shortify
- Summary: Stock falls 5.2% even as Freedom Capital Markets initiates bullish coverage with $97 price target. Positive analyst calls don't always move stocks; market…
- Keywords: inspire medical systems, insp, freedom capital markets, analyst upgrade, medical device, stock decline, price target, market skepticism, valuation concerns, Inspire, Medical, drops
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/inspire-medical-systems-drops-5-2-after-freedom-capital-markets-maintains-buy
- Author: AlphaStreet Newsdesk
- Published: 2026-09-22T19:32:36+00:00
- Read time: 1 min
- Topics: inspire medical systems, insp, freedom capital markets, analyst upgrade, medical device, stock decline, price target, market skepticism, valuation concerns
## Inspire stock falls despite upgrade
Inspire Medical Systems shares dropped 5.2% to $71.80 on Tuesday, even as Freedom Capital Markets initiated coverage with a Buy rating and $97 price target.

> Inspire Medical Systems shares fell 5.2% on Tuesday despite an analyst upgrade
## The disconnect explained
The $97 target represents 36.6% upside, yet investors sold on heavy volume of 592,044 shares, suggesting skepticism about the analyst's bullish thesis.
## Valuation concerns may dominate
The selloff signals broader worries about valuation, competitive positioning, or near-term growth prospects that the analyst's optimistic outlook doesn't fully address.
## Market environment for med devices
When positive analyst actions fail to lift shares, it often reflects stretched valuations, profit-taking, or macro headwinds that overshadow individual catalysts.
## What investors should watch
Monitor whether other analysts follow with upgrades, track clinical data and regulatory milestones, and watch if the stock can reverse Tuesday's decline and validate the $97 target.
## Key takeaway

Positive analyst calls don't always move stocks; market skepticism can override bullish ratings when investors worry about valuation or growth.